A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma

Hematology/Oncology Clinics of North America

Volumn 16, Issue 1, 2002, Pages 123-138

  Kozuch, Peter ^a   Petryk, Magdalena ^a   Bruckner, Howard W ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ALTRETAMINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; RUBITECAN; STREPTOZOCIN; TAXANE DERIVATIVE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MULTICENTER STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; ENZYME INHIBITORS; EPIRUBICIN; FLUOROURACIL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INTERFERON ALFA-2B; LEUCOVORIN; MULTICENTER STUDIES; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RESPIRATORY DISTRESS SYNDROME, ADULT; TAXOIDS; TREATMENT OUTCOME;

EID: 0036259139     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00004-1     Document Type: Review

References (67)

1. Gemcitabine: Preclinical pharmacology and mechanisms of action
2. Phase II trial of gemcitabine (2,2′-difluoroxycytidine) in patients with adenocarcinoma of the pancreas
3. Storniolo, Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
4. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with pancreas cancer: A randomized trial
5. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
6. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma
7. Randomized phase III trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma
8. Gemcitabine: Current status of phase I and II trials
9. Fatal pulmonary toxicity resulting from treatment with gemcitabine
10. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy
11. The integration of chemotherapy into a combined modality approach for cancer treatment.VI.Pancreatic adenocarcinoma
12. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouraciland doxorunbicin vs fluorouracil, doxorobicin, and mitomycin
13. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
14. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial
15. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma
16. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas
17. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N- (phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers
18. A phase II study of weekly 24-h infusion of high-dose 5-flourouracil in advanced pancreatic cancer
19. A phase II trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer
20. Phase II trial of CPT-II in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
21. CPT-II in gastrointestinal cancer
22. Intrinsic anticancer activity of 9-nitrocamptothecin ((NC or RFS 2000) compared to 9-aminocamptothecin
23. A phase II study of rubitecan (RSF 2000 9NC, 9-nitro-20(S)-camptothecin) in patients with refractory pancreatic cancer
24. Final results of a phase Il study of dx-8951f (exatecan mesylate, dx) in advanced pancreatic cancer
25. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinomas
26. Phase Il study of taxotere(RP56976, docetaxel)in pancreatic adenocarcinoma
27. Phase II study of docetaxel as first line chemotherapy in metastatic adenocarcinoma of the pancreas
28. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas
29. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM)
30. A phase III trial on the therapy of advanced pancreatic carcinoma, Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin
31. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
32. Chemotherapy in pancreatic cancer: Result of a controlled, prospective, randomised, multicentre trial
33. Chemotherapy prolongs Survival in inoperable pancreatic carcinoma
34. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozocin, and mitomycin (FSM)
35. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal carcinomas
36. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma
37. Efficacy of 5FU + Cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG)
38. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma
39. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma
40. 5-Fluorouracil/cisplatin in the treatment of advanced pancreatic cancer
41. Randomized phase II study of oxaliplatin alone, 5-fluorouracil alone, and the two drugs combined in advanced or metastatic pancreatic adenocarcinoma
42. A Phase III Study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): An Eastern Cooperative Oncology Group (ECOG) trial
43. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer (APC): A GOIRC randomized phase II trial
44. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU, bolus and infusion, and gemcitabine (FOLFUGEM Regimen)
45. In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma
46. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study
47. Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: Preliminary results of a randomized phase III trial
48. Randomized trial of gemcitabine alone or with cisplatin in the treatment of advanced pancreatic cancer: A phase II multicenter study of the Southern Italy Oncology Group
49. Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): A Gercor Multicenter phase II study
50. Multicenter phase II trial of first-line irinotecan and gemcitabine in patients with locally advanced or metastatic pancreatic cancer
51. Front-line treatment of pancreatic carcinoma with gemcitabine in combination with irinotecan: Preliminary results of a multicenter phase II study
52. A phase I Il study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
53. A phase I/II study of gemcitabine and docetaxel in patients with unresectable pancreatic cancer
54. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion flourouracil, and gemcitabine in stage IV pancreatic adenocarcinoma
55. Phase II study of a combination with leucovorin (LV), 5 FU bolus and infusion (FU), gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced (I.A) and metastatic (M) pancreatic carcinoma (APC)
56. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non-crossresistant regimen for refractory metastatic adenocarcinoma of the exocrine pancreas
57. Activity of cisplatin in adenocarcinoma of the pancreas
58. Randomized phase Il clinical trial of adriamycin, methotrexate and actinomycin D in advanced measurable pancreatic carcinoma
59. A phase II study evaluating the tolerability and efficacy of Caelyx (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma
60. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue
61. Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas
62. Ifosfamide and mesna: Marginally active in patients with advanced carcinoma of the pancreas
63. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma
64. Phase II trials of hexamethylmelamine, dianhydrogalactito I. Razoxane and 2′-deoxythioguanosine as single agents against advanced measurable tumor of the pancreas
65. Phase II evaluation the melphalan in adenocarcinoma of the pancreas
66. Randomized trial of 5-FU and mitomycin-C with or without streptozoein for advanced pancreatic cancer
67. Phase II study of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mytomycin-C and two regimens of streptozocin plus miytomycin-C plus fluorouracil